Cantor Fitzgerald downgraded Astria Therapeutics (ATXS) to Neutral from Overweight.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Is ATXS a Buy, Before Earnings?
- Astria Therapeutics announces final results from ALPHA-STAR trial
- Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment
- Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward
- Astria Therapeutics downgraded to Neutral from Buy at H.C. Wainwright